Targeted Medical Pharma Products

Amino Acid Technology for Anemia

According to the Centers for Disease Control and Prevention, anemia affects 18% of women ages 12-49 and 18.6% of all nursing home residents in the United States. Causes of anemia include nutritional deficiencies, inherited genetic defects, medication-related side effects, and chronic disease. It can also occur because of blood loss from injury or internal bleeding, the destruction of red blood cells, or insufficient red blood cell production.

Anemia is a blood disorder that slows the production of red blood cells in the bone marrow. Various chronic infections, inflammatory diseases and other illnesses and medications can affect the body’s ability to produce red blood cells. Some of these chronic conditions include certain cancers, autoimmune diseases such as rheumatoid arthritis, as well as HIV/AIDS, hepatitis C, liver disease and heart failure. Certain treatments for chronic disease can also cause anemia. Chemotherapy and radiation can impair the bone marrow's production of red blood cells,  treatments for hepatitis C can induce anemia. Certain HIV or AIDS treatments can also lead to anemia in particular the drug AZT. Other medications that increase the risk for anemia are certain antibiotics, some antiseizure medications (phenytoin), immunosuppressive drugs (methotrexate, azathioprine), antiarrhythmic drugs (procainamide, quinidine), and anti-clotting drugs (aspirin, warfarin, clopidogrel, heparin).

In 2013, TRGM commenced the development of the first amino acid based treatment for anemia. The initial pilot study of patients with mild to moderate anemia taking the ESS product showed an increase in hemoglobin levels by an average of 11.39 percent.  The average baseline hemoglobin measurement was 10.08 and 11.21 after 45 days with a similar increase in reticulocyte count (p<0.01). The company is currently engaged in a third open label clinical trial with the product. For future alerts about the product sign up here: